Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated at

Investment analysts at started coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

Shares of NYSE AMPE opened at $0.30 on Wednesday. Ampio Pharmaceuticals has a twelve month low of $0.20 and a twelve month high of $9.71. The stock has a market capitalization of $4.53 million, a price-to-earnings ratio of -0.16 and a beta of 1.70.

About Ampio Pharmaceuticals

(Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.

Further Reading

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with's FREE daily email newsletter.